Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
16.11.
2021

Redeye returns with a follow up-note to Genovis’ Q3’21 report. We believe that the third quarter is just a bump in the road and continue to have a very positive long-term view.

Muut analyysit
12.11.
2021

Redeye provides an initial take on Genovis’ Q3 report. We argue that it is a relatively weak report as the sales growth was only 10% (low for Genovis). However, the third quarter is a seasonally weaker quarter for the company.

Tiedotteet
12.11.
2021
July - September 2021    
  • Net sales rose by 10% to SEK 15,699 (14,216) thousand.
Muut analyysit
2.11.
2021

Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – adeal that clearly validates the huge potential in the company and its SmartEnzymes.

Tiedotteet
2.11.
2021

Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – a deal that clearly validates the huge potential in the company and its SmartEnzymes. We have hiked our fair value range and argue that the stock is very attractive for the long-term investor thanks to significant optionality on the upside.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Muut analyysit
21.10.
2021

Redeye provides a first comment on today’s news regarding the strategic licensing deal with Selecta Bioscience.

Tiedotteet
21.10.
2021

Under the agreement Genovis grants Selecta exclusive license to develop and promote a proprietary IgG protease, Xork™, as a potential pre-treatment prior to the administration of gene therapy and for autoimmune diseases. 

Under the terms of the license:
  • Genovis will receive USD 6 million in upfront and early preclinical milestone payments and is eligible for up to USD 598 million in development, regulatory and sales milestone payments. Additionally, Genovis will receive double digit royalties on sales.

Muut analyysit
6.10.
2021

Redeye gives a short comment on today’s announcement that Genovis has hired Magnus Långberg as the new CFO of the Group.

Tiedotteet
6.10.
2021

Genovis has hired Magnus Långberg as the new CFO of the Group; he will begin in January 2022.

Magnus Långberg has over 20 years of experience from a variety of positions within finance and management at international life science companies. He will be joining Genovis from his most recent position at Hemocue AB. Before that he worked at companies such as QPharma and BD Medical.

Muut analyysit
13.8.
2021

Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-term view of the case.

Genovis AB